Related Experiment Video

Updated: Apr 17, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.7K

[Pediatric pulmonary hypertension]

D Dunbar Ivy, Steven H Abman, Robyn J Barst

    Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir
    |February 21, 2015
    PubMed

    Insights

    Pediatric pulmonary hypertension (PH) is a serious condition in children, often linked to congenital heart disease. Management challenges persist due to reliance on adult data and expert experience.

    Area of Science:

    • Pediatric Cardiology
    • Pulmonary Medicine
    • Rare Diseases

    Context:

    • Pulmonary hypertension (PH) significantly impacts pediatric morbidity and mortality.
    • Common causes in children include idiopathic PH and congenital heart disease (CHD).
    • Incidence rates highlight the prevalence of PH associated with CHD in pediatric populations.

    Purpose:

    • To review the classification and management of pediatric pulmonary hypertension.
    • To address the challenges in diagnosing and treating PH in infants, children, and newborns.
    • To highlight the evolving understanding of PH in relation to CHD and developmental lung diseases.

    Summary:

    • Pediatric PH is rare but serious, with idiopathic and CHD-associated forms being most common.
    • Updated classifications now better incorporate CHD and neonatal/developmental lung conditions.
    • Current management relies heavily on adult studies and expert clinical judgment, posing challenges.

    Impact:

    • Improved classification aids in better understanding and diagnosis of pediatric PH.
    • Highlights the need for pediatric-specific evidence in treatment strategies.
    • Emphasizes the critical role of expert experience in managing complex pediatric cases.

    More Related Videos

    Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice10:20

    Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

    Published on: January 16, 2013

    26.2K
    Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet09:22

    Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet

    Published on: November 4, 2015

    12.7K

    Related Concept Videos

    Pulmonary Hypertension: Classification and Pathogenesis01:30

    Pulmonary Hypertension: Classification and Pathogenesis

    Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
    There are various classifications for PH, each relating to different underlying causes and also...
    898
    Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

    Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

    Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
    Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
    804
    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
    667
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
    362
    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

    Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
    ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
    577
    Pulmonary Embolism I: Introduction01:29

    Pulmonary Embolism I: Introduction

    Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
    1.4K